FDA-approved Drug for Relapsed Follicular Lymphoma in Adults

Copanlisib, a kinase inhibitor, has received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of follicular lymphoma in adults that has relapsed despite at least two prior treatments. The approval comes following the positive results with the drug in a part of the Phase II clinical trial called the CHRONOS-1 study.
Email bookmark
Font : A-A+

Related Links